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http://dx.doi.org/10.1016/j.ccr.2013.06.005SUMMARYSenescence, perceived as a cancer barrier, is paradoxically associated with inflammation, which promotes
tumorigenesis. Here, we characterize a distinct low-grade inflammatory process in stressed epithelium that is
related to para-inflammation; this process either represses or promotes tumorigenesis, depending on p53
activity. Csnk1a1 (CKIa) downregulation induces a senescence-associated inflammatory response (SIR)
with growth arrest in colorectal tumors, which loses its growth control capacity in the absence of p53 and
instead, accelerates growth and invasiveness. Corresponding processes occur inCKIa-deleted intestinal or-
ganoids, assuming tumorigenic transformation properties ex vivo, upon p53 loss. Treatment of organoids
andmicewith anti-inflammatory agents suppresses the SIR and prevents p53-deficient organoid transforma-
tion and mouse carcinogenesis. SIR/para-inflammation suppression may therefore constitute a key mecha-
nism in the anticarcinogenic effects of nonsteroidal anti-inflammatory drugs.INTRODUCTION
Intrinsic DNA damage response and cellular senescence have
recently been implicated as major foundations of the barrier
against tumor progression (Bartkova et al., 2006; Nardella
et al., 2011; Ventura et al., 2007; Xue et al., 2007). Whereas
normal cells senesce primarily through the mechanism of repli-
cative senescence—namely, progressive erosion of telomeres
accompanied by double-strand breaks and a DNA damage
response (DDR), most cancer cells evade this mechanism by vir-
tue of persistent telomerase activity (Collado et al., 2007). How-
ever, some cancer cells bear telomere dysfunction (MeekerSignificance
Nonsteroidal anti-inflammatory drugs (NSAIDs) have remarkab
nogenic mechanism of action is largely elusive. Most human ca
not display overt inflammation. Para-inflammation, defined a
inflammation, is implicated in chronic human diseases, such as
a senescence-inflammatory response (SIR) as a form of para-
We show that the senescence process has paradoxical tum
and describe a distinct mode of action of NSAIDs—suppres
polyps imply similar effects of para-inflammation in human ne
242 Cancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc.et al., 2004) and most others are vulnerable to different senes-
cence-provoking mechanisms, such as oncogene-induced
senescence (OIS) and senescence associated with loss of
certain tumor suppressors (Nardella et al., 2011). Mechanisti-
cally, OIS is the best-characterized process; similar to replicative
senescence, OIS induces DDR, with subsequent activation of
p53 and p21, imposing growth arrest (Bartkova et al., 2006).
Mechanisms of OIS have been studied both in vitro and in vivo,
indicating an essential role of cytokines and chemokines in sus-
taining senescence (Acosta et al., 2008; Kuilman et al., 2008).
The importance of senescence as a tumor barrier has been indi-
cated in mouse models of tumorigenesis and is supported byle effects in suppressing carcinogenesis, yet their anticarci-
ncers that are affected by NSAIDs develop in tissues that do
s an intermediate between basal homeostasis and chronic
diabetes mellitus and atherosclerosis. Here we characterize
inflammation following a persistent DNA damage response.
or promotion effect in a mouse model of intestinal cancer
sion of SIR/para-inflammation. Studies of human intestinal
oplasia.
Figure 1. CKIa Loss Is Associated with Cell Cycle Arrest in Human Colorectal Polyps
(A) Immunohistochemistry (IHC) of CKIa, KI67, and Pan-CYTOKERATIN in serial sections of two representative human colonic polyps (n = 18). Demarcated are
examples of CKIa-low and corresponding KI67-low staining regions. CKIa staining in adjacent normal colon is shown for comparison. Pan-CYTOKERATIN: a
general epithelial marker.
(B) Quantification of CKIa/KI67 correlation. 18 regions within seven polyps were scored for percentage of KI67-positive staining in CKIa-low compared with
CKIa-high stained regions (average ± SEM). *p = 0.02.
See also Figure S1.
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senescence-associated b-galactosidase activity (SA-b-gal),
there is apparently little in common between senescence pheno-
types of different tissues, implying that certain senescence attri-
butes would be tissue specific. Another factor implicated in
most, but not all types of senescence is p53 (Leal et al., 2008);
its inactivation is thought to eliminate senescence in vivo.
Whereas the bulk of accumulating data indicates that senes-
cence impedes tumor progression, Campisi and colleagues
documented an opposing function of senescence in tumorigen-
esis. Accordingly, senescent cells cocultured with tumor cells
secrete cytokines, chemokines, and growth factors, denoted
senescence-associated secretory phenotype (SASP), which
facilitate tumor cell growth (Coppe´ et al., 2010a). Xenotransplan-
tation of senescent cells with fully malignant cancer cells
markedly accelerates the rate of tumor formation in mice (Bar-
tholomew et al., 2009; Bhatia et al., 2008; Coppe´ et al., 2010b;
Krtolica et al., 2001; Liu and Hornsby, 2007). However, whether
senescence facilitates tumorigenesis in a nontransplanted tumor
model and if senescence of the epithelial tumor progenitors
themselves, rather than associated stromal cells, can also pro-
mote tumorigenesis is not known. Elucidating the mechanisms
and effects of senescence in the context of an intact tissue is
important because the protumorigenic function of senescence
may explain the vastly increased frequency of cancer at old
age and constitute a possible therapeutic target for cancer pre-
vention and treatment.
RESULTS
CKIa Loss in Mouse and Human Benign Intestinal
Tumors Is Associated with Senescence and Growth
Arrest
CKIa ablation in the mouse gut epithelium (CKIaDgut) triggers
extensive Wnt hyperinduction, yet Wnt-associated excessiveproliferation and tumorigenesis are conspicuously absent and
gut homeostasis is maintained (Elyada et al., 2011). Thus, CKIa
loss is distinguished from other modes of Wnt hyperactivation
(e.g., APC ablation) by an extensive DDR, p53/p21-dependent
growth arrest, and senescence, likely counteracting the propro-
liferative and protumorigenic effects of Wnt hyperinduction
(Elyada et al., 2011). CKIa down-modulation could therefore
act as a safeguard mechanism to inhibit aberrant Wnt-induced
growth processes.
To assess the pathophysiologic relevance of CKIa loss in
precancerous lesions, we examined human andmouse intestinal
tumors for CKIa expression with immunohistochemistry (IHC).
Whereas CKIa expression was homogeneous across normal
gut epithelium, heterogeneous expression was found in most
tested adenoma regions in human (16 of 18) andAPCMin/+mouse
(34 of 40) gut (Figure 1A; Figure S1A available online, respec-
tively). Low CKIa-expressing foci were consistently KI67-low in
both human and mouse polyps, indicating that affected cells
exit the cell cycle (Figure 1; Figure S1). Moreover, reduced
CKIa staining in sequential sections of mouse adenomas also
correlated with SA-b-gal activity (Figure S1), indicating an asso-
ciation between CKIa loss, senescence, and growth arrest.
Taken together, these data suggest that CKIa down-modulation
could play a role in inducing senescence and growth arrest in
premalignant colorectal tumors.
Absence of CKIa in the Mouse Gut Triggers a Distinct,
Low-Grade Senescence-Associated Inflammatory
Response
Cellular senescence has distinct inflammatory features that
function both to maintain the process via an autocrine
loop (Bartek et al., 2008) and to affect neighboring cells via para-
crine signaling (Acosta et al., 2008). The senescence-inflamma-
tory response (SIR) is partly related to the previously described
senescence-associated secretory phenotype (SASP) andCancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc. 243
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Kuilman and Peeper, 2009), which vary from one cell type to
another (Kuilman and Peeper, 2009). These programmatic in-
flammatory responses are distinguished from acute or chronic
inflammatory reactions and harbor noninflammatory secretory
mediators, such as growth factors and various receptor proteins
(Acosta et al., 2008; Collado and Serrano, 2006; Coppe´ et al.,
2008; Kuilman et al., 2008; Kuilman and Peeper, 2009).
Per histology and IHC analysis, CKIaDgut (knockout, KO) mice
did not show any obvious signs of cellular inflammation:
lymphocyte and macrophage numbers in the lamina propria
were similar to, or even lower than wild-type (WT) and heterozy-
gous (CKIa+/Dgut, Het) mice (Figure 2A). Flow cytometry com-
parison of small bowel mucosal cell populations between
CKIaDgut and CKIa+/Dgut even showed a slight reduction in the
abundance of immune/inflammatory CD45-positive cells (Fig-
ures 2B and 2C). On the other hand, comparative RNA-seq
analysis of CKIaDgut versus WT and CKIa+/Dgut enterocytes,
and further validation of individual genes with qRT-PCR and
IHC analysis, revealed a marked increase in the expression of
many immune and inflammatory genes (Figures 2D and 2E),
along with the senescence markers SA-b-gal (Figure 2F),
p19ARF, and the senescence-associated lysosomal abundance
marker LAMP-2A (Cho and Hwang, 2011; Figure 2G). Among
the upregulated inflammatory genes are soluble agents (e.g.,
Tnf and IL1rn), TNF-receptor family members (e.g., Opg and
Troy), Toll-like receptors (Tlr; e.g., Tlr1 and Tlr2), interferon
response genes (e.g., Ifit2 and Oas2), inflammatory enzymes
(e.g., Pla2g2a, and Ptges), and transcription factors (e.g.,
Sox17 and Rel). A list of the inflammation and senescence-
associated genes representing SIR is depicted in a heatmap
(Figure 2D), indicating the relative gene expression of CKIa
KO and CKIaDgut;p53Dgut double knockout (DKO) enterocytes
(Elyada et al., 2011) compared to CKIa Het enterocytes. A com-
parison of the SIR list to a compilation of SASP/SMS based on
previous studies (Acosta et al., 2008; Collado and Serrano,
2006; Coppe´ et al., 2008; Kuilman et al., 2008; Kuilman and
Peeper, 2009) shows a relatively small overlap between SIR
and SASP (Figure 2D), suggesting that SIR and SASP may
have some common features, yet are mostly distinct. Further-
more, in accordance with the paucity of many secreted factors,
particularly chemokines in the CKIa KO and DKO gut, gene setFigure 2. Ablation of CKIa in the Mouse Gut Triggers a Senescence-In
(A) Automated image analysis quantification (Ariol-SL50) of mouse intestinal sec
CKIa+/Dgut (Het) (n = 4 and n = 2, respectively) and CKIaDgut (KO; n = 5 and n = 3,
units ± SEM (n.s., nonsignificant) is depicted.
(B and C) FACS analysis of the leukocyte common antigen CD45.2 in intestina
representative analysis is shown in (B), where CD45.2-positive population is dem
(D) Heatmap of the expression change of senescence- and inflammatory-associ
logarithm of the fold change in comparison to CKIa heterozygous IECs. Gene sym
genes (blue), or both (purple). The SASP gene set was compiled from the literatu
Peeper, 2009). SIR genes were defined as senescence- and inflammation-associa
(KO and DKO).
(E) Quantitative real-time PCR (qRT-PCR) analysis of inflammatory genes in IECs is
(n = 4), day 5 (n = 6), and day 8 (n = 5), normalized to CKIa Het mice (n = 8; mea
(F) Senescence-associated b-galactosidase (SA-b-gal) staining (blue) of CKIaD
Counterstain: nuclear fast red.
(G) IHC analyses of the SIR markers LAMP-2A, p19ARF, PTGES, and sPLA2 in i
(H) Double immunofluorescence (IF) of sPLA2 and PTGES in an intestinal section
See also Figure S2.enrichment analysis comparison of SIR and SASP mostly indi-
cates a negative correlation (Figure S2).
To test whether the inflammatory component of SIR is a cell-
autonomous property of senescence-marked enterocytes, gut
sections were analyzed with IHC and immunofluorescence (IF)
for senescence markers, of which prostaglandin E2 synthase
(PTGES, also known as microsomal oxidoreductase, mPGES1),
an inflammatory enzyme that is also a strong oncogene-induced
senescence indicator (Kuilman et al., 2008), was highly induced
inCKIa-ablated gut (Figure 2G). The inflammatory enzyme phos-
pholipase A2 (sPLA2; Fijneman et al., 2009), highly scored in
the RNA-seq-derived heatmap (Pla2g2a), is also strongly ex-
pressed in CKIa-deficient intestinal sections (Figure 2G), and
double IF of PTGES and sPLA2 demonstrates a complete
expression overlap between these two genes (Figure 2H). It
therefore appears that the inflammatory response is a cell-
autonomous property of senescing cells.
SIR Effects in the Absence of p53 and p21
Several studies have attributed cellular senescence to the acti-
vation of p53 and p21; Pten loss-induced senescence was
abrogated in p53-deficient mice and Ras oncogene-induced
senescence was observed in liver tumors upon p53 reactivation
(Nardella et al., 2011; Xue et al., 2007). To assess the role of p53
and p21 in the cellular senescence induced in CKIaDgut, we
examined SIR components in doubly deficient CKIaDgut;p53Dgut
and CKIaDgut;p21/ mice (CKIa;p53 or CKIa;p21 DKO, respec-
tively; Elyada et al., 2011). Surprisingly, the senescence indica-
tors SA-b-gal, p19ARF, PTGES/mPGES1, and the inflammatory
gene set remained prominent in both CKIa;p53 DKO and
CKIa;p21 DKO gut (Figures 3A and 3B). p21 is a potent p53-
induced growth suppressor in most cell types (Abbas and Dutta,
2009) and is the most prominent cyclin-dependent kinase inhib-
itor associated with CKIa KO-induced senescence in the mouse
gut (Elyada et al., 2011). As expected, SA-b-gal activity and BrdU
incorporation were mostly mutually exclusive in the CKIaDgut
bowel (Figures 3C and 3D), yet unexpectedly concur in both
CKIa;p21 and CKIa;p53 DKO intestines (Figures 3C and 3D).
The uncoupling of SA-b-gal activity from growth arrest and the
dramatic intestinal carcinogenesis characterizing DKO mice
suggest that SIR loses its cancer-protective role in the absence
of p21, either primarily or secondarily to p53 deficiency. IHCflammatory Response
tions stained for the T cell marker CD3 and the macrophage marker F4/80 in
respectively). The mean percentage of positive-stained area within crypt-villus
l epithelial cells (IECs) isolated from CKIa Het (n = 2) and KO (n = 3) mice. A
arcated in red. Mean percentage ± SEM is shown in (C).
ated genes in CKIa KO and CKIa;p53 DKO IECs. Heatmap colors indicate the
bols are color-coded to indicate genes designated as SIR genes (red), SASP
re (Acosta et al., 2008; Coppe´ et al., 2008; Kuilman et al., 2008; Kuilman and
ted genes that showed at least 2-fold upregulation averaged in both conditions
olated fromCKIaKOmice at different time points following KO induction: day 2
n ± SEM). *p < 0.05 (compared to day 2).
gut mouse intestinal cryo-sections from 2, 5, and 8 days post-KO induction.
ntestinal sections of CKIa Het and KO mice.
of CKIa KO mice.
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Figure 3. Extinction of Either p53 or p21 in CKIa-Deficient Gut Uncouples SIR from Growth Arrest
(A) SA-b-gal staining (blue, counterstain: nuclear fast red) and IHC analyses of PTGES and p19ARF in intestinal cryo-sections and paraffin sections, respectively,
of CKIa KO, CKIa;p53 DKO, and CKIa;p21 DKO mice. Het control for the two IHCs is shown in Figure 2G.
(B) qRT-PCR analysis of SIR genes in IECs of Het (n = 4),CKIaKO (n = 8),CKIa;p53DKO (n = 8), andCKIa;p21DKO (n = 8; mean ± SEM). *p < 0.05, yp = 0.06–0.07.
The y axis is presented as Log10.
(C) Double staining of SA-b-gal and BrdU in intestinal cryo-sections of CKIa KO, CKIa;p21, and CKIa;p53 DKO mice. White arrows mark cells that are costained
with SA-b-gal and BrdU.
(D) Quantification of SA-b-gal/BrdU costained cells versus total SA-b-gal-positive cells in CKIa KO, CKIa;p21, and CKIa;p53 DKO sections shown in (C). n = 93,
n = 58, and n = 72, respectively; mean ± SEM. *p = 0.04, yp = 0.07.
(E) Double staining of SA-b-gal (blue) and PROX1 (brown) in invasive clusters of the small intestine in a representative intestinal cryo-section of a CKIa;p21 DKO
mouse. Black triangles mark the double-positive clusters (n = 213/216 clusters). Counterstain: nuclear fast red.
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ping immunostaining of the senescence indicators SA-b-gal and
the transcription factor PROX1 (Figure 3E), which is tightly asso-
ciated with high-grade dysplasia and invasive phenotype in hu-
man and mouse gut (Elyada et al., 2011; Petrova et al., 2008),
raising the hypothesis that under particular circumstances,
such as loss of p53, paracrine effects of SIR might promote inva-
sion and carcinogenesis. This assumption would be in line with
in vitro studies by Coppe´ and colleagues showing that senes-
cence may drive tumorigenesis via paracrine effects of a senes-
cence-associated secretory phenotype (SASP; Coppe´ et al.,
2008). Yet, unlike the SASP effects, the entire ground of SIR
action could be the epithelium proper, not requiring additional
pathology in the stromal component.
Senescing Epithelial Organoids Are Rescued by p53
Deficiency, while Assuming a Transformed Phenotype
To study the effects of senescence in an isolated tissue
composed solely of epithelial cells, we induced CKIa deletion
in gut epithelial organoids ex vivo. Cellular senescence is a
fundamental protective mechanism, but its physiologic role in
different tissues, or different cell types in a given tissue, is mostly
obscure. Epithelial organoids were prepared from floxed CKIa
and doubly floxed CKIa;p53 mice and treated in culture with
4-hydroxy-tamoxifen (4OHT), producing single CKIa deletion
(SKO) and double CKIa;p53 deletion (DKO), respectively (Fig-
ure S3A). Similar to the effect in gut mucosa, both SKO
and DKO organoids activate senescence markers, such as
p19ARF, LAMP-2A (Cho and Hwang, 2011; Collado et al.,
2007), and the SIR gene set, in response to CKIa ablation (Fig-
ures 4A–4D). However, while SKO organoids undergo growth
arrest, evident by lack of BrdU incorporation (Figure 4E), express
p21 (Figures 4F and 4G), and disintegrate within 4–5 days (Fig-
ures 4H and 4I), DKO organoids thrive in culture for many weeks
without growth factors and Wnt activators (Figures 4I and 4J),
showing extensive incorporation of BrdU (Figure 4K). Notably,
both SKO and DKO organoids acquired a different morphology
compared to their nondeleted floxed counterparts: a spherical
compact structure, without the crypt-like outpockets that char-
acterize WT and nondeleted organoids (Figure 4H). BrdU incor-
poration analysis of the organoids in comparison to their
nondeleted counterparts indicated that while proliferation was
restricted to the crypt-like outpockets in the WT organoids
(CKIaflfl and CKIafl/fl;p53fl/fl), it encompassed the entire organoid
volume in DKO cultures (Figure 4K), indicating that following
ablation, DKO organoids acquired a proliferative crypt pheno-
type that characterizes colonic tumors (Sato et al., 2011).
Intestinal organoids are purely epithelial and do not bear
lamina propria and other stromal components. Therefore,
invasiveness cannot be observed in organoids as part of the
‘‘transformed’’ phenotype. Nevertheless, we could measure
expression of genes belonging to the proinvasive gene expres-
sion signature (denoted PSIS), characterizing invasive epithelial
foci at the lamina propria of DKO mice (Elyada et al., 2011).
Several PSIS genes were upregulated following tamoxifen in-
duction of doubly floxed CKIa;p53 organoids (Figure S3B), and
immunostaining of DKO organoids revealed a remarkable induc-
tion of the PSIS gene Prox1, compared to control (Figure 4L). It
therefore appears that the ablation of p53 switches the fate ofthe senescing intestinal organoids from rapid decay to immortal-
ization with a transformed phenotype, including bulk prolifera-
tion, loss of normal crypt-villous architecture, and acquisition
of proinvasive properties (expression of PSIS markers).
Inflammatory Mediators Are Needed to Maintain the
Transformed Phenotype of DKO Organoids
Similar to theCKIa-deleted gut mucosa, organoid senescence is
associated with the expression of a set of inflammatory media-
tors (Figure 4D). To assess the contribution of the inflammatory
repertoire to the organoid fate, we treated SKO and DKO
organoids with the nonsteroidal anti-inflammatory drug (NSAID)
sulindac and with the IkB kinase (IKK) inhibitor BOT64 (Kim
et al., 2008). Treated SKO organoids showed significant reduc-
tion in the senescence markers LAMP-2A and p21 (Figures 5A–
5C) and regained some incorporation of BrdU (Figure 5D).
Accordingly, NSAID-treated SKO organoids presented a 20%
prolonged life span compared to their nontreated counterparts
(Figures 5E and 5F). Remarkably, treatment of DKO organoids
with anti-inflammatory drugs mitigated the proliferative crypt
phenotype, restoring the normal budding phenotype observed
inWTorCKIafl/fl;p53fl/fl organoids (Figures 6A–6D), in association
with SIR gene inhibition (Figure 6E). This reversionwas accompa-
niedwith a redistribution of BrdU incorporation from the spheroid
core body to the periphery and outpockets (Figure 6F) and a
marked suppression of PSIS induction (Figures S4A–S4C). Sulin-
dac-dependent inflammatory and invasive signature (PSIS) sup-
pression was apparent as early as 16 hr after treatment initiation
and lasted at least 5 days (Figures S4A and S4B). IHC analysis in
treated DKO organoids confirmed PSIS suppression by NSAIDs,
showingmarkedly reduced expression of PROX1 (Figure 6G); re-
sidual PROX1 expression was mainly observed at the budding
outpockets, corresponding to its occasional expression in the
bottom of intestinal crypts (Petrova et al., 2008). Collectively,
this implies that both the aberrant growth properties and the
invasion propensity of DKO organoids are SIR-dependent pro-
cesses, taking place in a stroma-free epithelial tissue.
DKO organoids were found to express significantly higher
levels of tumor necrosis factor (TNF) than organoids isolated
from APCDgut (APC KO) or WT mice (Figure 6H). To assess the
role of TNF in crypt organoid biology, we treated TNF-producing
DKO organoids and control APC KO organoids with anti-TNF
neutralizing antibodies. Anti-TNF consistently suppressed the
growth of DKO organoids by 15%–20% (size-wise and BrdU
incorporation at day 4), whereas it had no effect on APC KO or-
ganoids (Figures S4D and S4E). Notably, once organoids grow,
they may be mostly secluded from antibody effects (Sutherland
et al., 1987), possibly explaining the small, yet consistent and
highly significant effect. In line with these findings, exogenous
TNF treatment had a robust effect on WT organoids: it induced
aberrant growth and morphologic changes resembling the un-
treated DKO organoids; the ratio of budding organoids was
highly reduced following TNF treatment, BrdU incorporation
was redistributed from outpockets to the central sphere and
WT organoids acquired a proliferative crypt phenotype by day
4 (Figures 6I and 6J). Altogether, these data suggest that in the
absence of p53, contrary to the expected growth arrest, SIR pro-
motes an abnormal proliferative phenotype and an invasion spur
both in vivo and in purely epithelial intestinal organoid cultures.Cancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc. 247
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Based on the effects of SIR in organoid cultures, we tested
whether SIR has a role in carcinogenesis in vivo. First we tested
the effect of sulindac on CKIa KO mice and found that whereas
it repressed SIR as evident by SA-b-gal activity, p19ARF, p21,
and the SIR inflammatory genes (Figure S5A; Elyada et al.,
2011), SKO intestinal homeostasis was maintained. This is
probably due to balanced Wnt and p21 signaling because
both the protumorigenic and countertumorigenic signaling
arms were similarly repressed by the NSAID treatment (Fig-
ure S5B). In contrast, sulindac treatment spared both DDR
and p53 activation (Figures S5C and S5D). Next, we treated
CKIa;p21 DKO mice, which otherwise succumb to massive in-
testinal carcinogenesis within less than 2 weeks (Elyada et al.,
2011), with three anti-inflammatory agents having different
mechanisms of action: sulindac, BOT64, and BV6, a TNF
signaling inhibitor (Varfolomeev et al., 2007, 2012). All three re-
agents inhibited SIR in the gut of DKO mice, evident by a
reduction in SA-b-gal activity (Figures 7A and 7B), reduced
expression of PTGES/mPGES1 and sPLA2 inflammatory medi-
ators (Figure S5E), and a decrease in the levels of the inflamma-
tory gene set (Figure S5F) and p21 expression (Figure S5G).
Concomitantly, anti-inflammatory treatment suppressed the
expression of multiple proinvasive genes, which characterizes
the malignant lesions in this mouse model (Elyada et al.,
2011; Figures 7C–7E; Figures S5G–S5I), and subsequently sup-
pressed enterocyte proliferation and carcinogenesis of
CKIa;p21 DKO mice (Figures 7C–7F; Figure S5J). Treatment
with BV6 did not augment the already induced caspase-3 acti-
vation in DKO mice (Figure S5K), indicating that its anticarcino-
genic effect is not via induction of apoptosis.
Notably, whereas Wnt target gene expression was
suppressed by sulindac (Figures S5B and S5L), it was not
affected by BV6 and only mildly repressed by BOT64
(Figure S5M), indicating that the carcinogenic arrest was not
achieved via Wnt inhibition. In addition, all anti-inflammatory
treatments spared DDR and p53 activation (Figures S5N–
S5P). Collectively, these data indicate that the anticarcinogenic
effect of anti-inflammatory agents is via targeting SIR, distinct
from Wnt/b-catenin suppression.Figure 4. SIR Provokes SKO Organoid Decay, yet Transforms DKO Or
(A) qRT-PCR analysis of p19Arf in CKIafl/fl (noninduced control), CKIa KO (single
after 4-hydroxy-tamoxifen (4OHT) treatment (± SD). *p < 0.05.
(B) IF staining of p19ARF (green) in CKIafl/fl, SKO, and DKO organoids at day 5 aft
agarose gel and cut into sections prior to fixation and staining.
(C) IF analysis of LAMP-2A (green) in CKIafl/fl, SKO, and DKO organoids at day 5
(D) qRT-PCR analysis of SIR genes in SKO organoids, compared with their
Log2.
(E) IF analysis of BrdU incorporation (red) in Z-stack sections of CKIafl/fl and SKO
(F) qRT-PCR analysis of p21 in CKIafl/fl and SKO organoids (± SD). *p = 0.018.
(G) IF analysis of p21 (red) in SKO, DKO, and their floxed counterparts (CKIafl/fl a
Hoechst (blue).
(H) Representative bright-field images of day 4 organoids prepared from CKIafl/fl
arrows indicate live organoids after KO induction.
(I) Quantification of live organoids in SKO and DKO cultures compared with their
(J) Bright-field images of DKO organoid cultures, 5 days and 3 weeks after induc
(K) IF analysis of BrdU (orange) in DKO compared with floxed organoids. Counte
(L) IF analysis of PROX1 (light blue) in DKO compared with floxed organoids. Co
See also Figure S3.DISCUSSION
Inflammation is a protective response, primarily known to
confront and eliminate pathogens. However, it is often entwined
with a growth response that is needed for restoring tissue loss
following injury and infection. It thereby fulfills two complemen-
tary functions, countering infection and promoting tissue growth,
best evident in wound healing (Ben-Neriah and Karin, 2011).
Notably, hints of a relationship between inflammation and
abnormal cell growth can be found very early in metazoan evolu-
tion, perhaps as early as corals, which frequently exhibit
abnormal growths much like tumors (Squires, 1965). Tumors
have many characteristics in common with wound healing and
indeed were described as ‘‘wounds that won’t heal’’ (Dvorak,
1986).Whereas inflammation is emerging as one of the hallmarks
of cancer (Hanahan andWeinberg, 2011), its role in most tumors
is not well understood. Only a minority of solid tumors is associ-
ated with overt inflammation (Coussens and Werb, 2002), but
long-term treatment with NSAIDs is remarkably effective in
reducing intestinal tumorigenesis in a mouse model (Beazer-
Barclay et al., 1996) and mortality rates associated with major
human solid tumors, by up to 75% (Burn et al., 2011; Chan
et al., 2009; Rothwell et al., 2010). These figures indicate that
inflammation may have many unrecognized faces, of which an
indolent course may be far more important factor in cancer
than previously appreciated. Medzhitov has coined a low-grade
inflammatory response ‘‘para-inflammation,’’ referring to an
adaptive response due to tissue stress or malfunction. This
response was proposed as an intermediate between the basal
homeostatic state and a classic inflammatory response and
hypothesized to underlie chronic inflammatory conditions that
are associated with common human diseases, such as athero-
sclerosis, diabetes mellitus, and neurodegeneration (Medzhitov,
2008). Based on our study, we presume that this theoretical
concept may be extended to another disease category, now
with experimental evidence, implicating para-inflammation in
tumorigenesis.
Whereas classical inflammatory reactions are primarily asso-
ciated with cell-exogenous insults, para-inflammation could
originate upon cell-endogenous insults; prominent examplesganoids
KO, SKO), and CKIa;p53 double KO (DKO) intestinal crypt organoids at day 5
er 4OHT treatment. Counterstain: DAPI (blue). Organoids were mounted in 3%
after 4OHT treatment. Counterstain: Hoechst (blue).
floxed counterparts (CKIafl/fl; ± SD). *p < 0.05. The y axis is presented as
organoids.
nd CKIa fl/fl;p53fl/fl, respectively) at day 5 after 4OHT treatment. Counterstain:
and CKIafl/fl;p53fl/fl with and without 4OHT treatment for KO induction. Black
noninduced counterparts at days 4 and 6 postinduction (± SD; nR 60).
tion with 4OHT.
rstain: Hoechst (white).
unterstain: Hoechst (white).
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Figure 5. Anti-Inflammatory Treatment Abrogates Senescence of SKO Organoids
(A) IF analysis of LAMP-2A (green) inCKIafl/fl, SKO, and SKO treated with 100 mMsulindac (SKOSul) and 2.5 mMBOT64 (SKOBOT) at day 5 after 4OHT treatment.
Counterstain: Hoechst (blue).
(B) Quantification of LAMP-2A-positive cells per organoid in each experimental group (± SD; nR 60). *p = 0.003, **p = 0.004.
(C) qRT-PCR analysis of p21 in SKO organoids treated with 100 mM sulindac (SKO Sul) or 2.5 mM BOT64 (SKO BOT) versus untreated SKO organoids and their
floxed counterparts (CKIafl/fl; ± SD) at day 5 after 4OHT induction.
(D) IF analysis of BrdU incorporation (red) in Z-stack sections of SKO organoids untreated or treated with 100 mMsulindac (SKO Sul) or 2.5 mMBOT64 (SKOBOT).
(E) Bright-field images of SKO organoids untreated or treated with 100 mM sulindac (SKO Sul) at day 5 postinduction and sulindac treatment. Dead organoids
were detected by staining with trypan blue.
(F) Ratio of live SKO and SKO + Sul organoids at days 4 and 5 postinduction and sulindac treatment (± SD; nR 60). *p = 0.009.
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Senescence Switch Promotes Colorectal Cancerare DNA damage and senescence, both of which are docu-
mented in colorectal tumorigenesis (Bartek et al., 2008; Bartkova
et al., 2006). However, it is unclear why colorectal polyps mani-
fest DDR and senescence. Although APCmutation-inducedWnt
hyperactivation could be a source of OIS in colorectal polyps,
senescence is not restricted to the highly hyperactivated prolifer-
ating zones of the polyp (Bartkova et al., 2006; Kuilman et al.,
2008), nor have we observed evidence for senescence or DDR
in APC-mutated aberrant crypt foci (pre-polyp regions; data
not shown). We therefore maintain that patchy CKIa loss in hu-
man and mouse APC-mutated, colorectal polyps has a distinct250 Cancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc.role beyondWnt activation, likely incorporating DDR for inducing
senescence. Such Wnt-DDR synergism prevails with intentional
CKIa ablation in the mouse gut and may therefore recapitulate
a human pathophysiologic phenomenon. It is likely that CKIa
ablation as a single genetic alteration may in fact mimic the
cumulative effect of multiple genetic alterations in human colo-
rectal cancer, many of which, like the Ras pathway mutations,
culminate in DDR and senescence (Collado and Serrano, 2010;
Figure 8).
Inflammatory mediators secreted from senescent cells have
been documented to modulate the tumor microenvironment
Figure 6. SIR Inhibition Reverts the Transformed DKO Phenotype Back to WT
(A) Bright-field images of DKO organoids untreated or treated with 500 mMsulindac (DKOSul; n = 2) compared with their floxed control (CKIa fl/fl;p53fl/fl) at day 5 of
treatment. Black arrows indicate budding organoids.
(B) Ratio of budding DKO and DKO + Sul organoids (± SD; nR 60). *p = 0.012.
(legend continued on next page)
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Senescence Switch Promotes Colorectal Cancerresulting in two apparently opposing roles: on one hand, tumor
inhibition via maintenance of prolonged to indefinite growth
arrest and immune clearance of the senescent cells (Bartkova
et al., 2005; Chen et al., 2005; Guerra et al., 2011; Kang et al.,
2011; Reimann et al., 2010; Ventura et al., 2007; Xue et al.,
2007), and conversely, tumor promotion via attraction of
tumor-supporting inflammatory cells, such as macrophages
and fibroblasts (Krtolica et al., 2001; Rakhra et al., 2010)
and angiogenesis (Sparmann and Bar-Sagi, 2004). We
now show how a senescence-associated para-inflammatory
response shifts its role from an antitumorigenic effector to a pro-
carcinogenic one, depending on the integrity of p53 and p21; in
the presence of functional p53 and p21, gut epithelial SIR is
coupled to growth arrest, whereas loss of either p53 or p21 un-
couples the two complementary processes and provokes
epithelial invasion into the lamina propria (Figure 3C). This may
herald the progression of a benign overgrowth to malignancy.
Notably, the SIR phenotype in CKIa-deficient gut is distinct
from other inflammatory reactions and bears only partial relation-
ship to the previously described SASP (Figure 2D). Epithelial SIR
features a distinct inflammatory profile that lacks most of the
chemokines, a hallmark of SASP, and accordingly is devoid of
a cellular inflammatory infiltrate. A similar process may com-
monly characterize human adenomatous polyps with patchy
CKIa loss and no obvious inflammatory infiltrate. This dual-pur-
pose autonomous inflammatory function is best evident in pure
epithelial organoid cultures derived from CKIa-deficient (SKO)
and CKIa;p53 doubly-deficient (DKO) gut epithelium, which
undergo senescence, generate their own internal microenviron-
ment, upregulate immune receptors, and produce TNF. Yet, the
fate of SKO and DKO organoids is quite distinct and is remark-
ably similar to that of the mucosa from which they are derived:
whereas the senescence process in SKO organoids culminates
in growth arrest as expected; in DKO organoids, it actively drives
a proliferative tumor-like crypt phenotype (Sato et al., 2011).
Likewise, treatment of WT organoids with TNF results in a similar
proliferative crypt morphology. Finally, treatment of the organo-
ids with anti-inflammatory agents moderates both the growth
promotion and proinvasive properties driven by SIR, in line
with their robust anticarcinogenic effect in DKO mice.
We show here that NSAID treatment strongly suppresses SIR
and abolishes both the tumor-like phenotype of DKO organoids
and carcinogenesis in DKO mice. Particularly robust is the sup-
pression of PSIS genes and certain proinflammatory enzymes,
notable among which are phospholipase A2 (Pla2g2a), lactoper-
oxidase (Lpo), and the prostaglandin E2 synthase Ptges/(C) Bright-field images of DKO organoids untreated or treated with 2.5 mM BOT
organoids.
(D) Ratio of budding DKO and BOT64-treated DKO (DKO BOT64) organoids (± S
(E) qRT-PCR analysis of SIR genes in DKO organoids and DKO treated with 5
(CKIa fl/fl;p53fl/fl; ± SD). *p < 0.05. The y axis is presented as Log2.
(F) IF analysis of BrdU incorporation (red) in Z-stack sections of DKO organoids
(G) IF analysis of PROX1 (red) in CKIa fl/fl;p53fl/fl DKO organoids untreated, and t
(H) qRT-PCR analysis of Tnf in WT (n = 6), 4OHT-induced APCfl/fl;Villin-Cre-ERT2
(I) Relative ratio of nonbudding WT organoids following a 4-day treatment with 10
*p = 0.002.
(J) BrdU labeling of WT organoids following a 3-day treatment with 1,000 U/ml e
BrdU-positive budding outpockets.
See also Figure S4.
252 Cancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc.mPGES1, a microsomal oxireductase that converts the COX-2
product PGH2 to PGE2. Prostaglandin E2 is associated with
invasiveness in many types of cancer (Greenhough et al.,
2009), yet the anticarcinogenic effect of NSAIDs ismostly related
to COX-2 inhibition (Wang and Dubois, 2010). Ptgs2, encoding
COX-2, is not a SIR gene, and unlike Ptges, it is not expressed
in the gut epithelium, but in the lamina propria (data not shown).
Interestingly, COX-2 is dispensable for DSS/AOM-induced colon
cancer in a mouse model (Ishikawa and Herschman, 2010),
possibly implying that in para-inflammation-associated cancer,
PTGES, rather than COX-2, could be the key carcinogenesis-
promoting target for NSAID inhibition. We therefore propose
that epithelial SIR/para-inflammation is a major factor in colo-
rectal tumor progression and its suppression may represent an
important mechanism for the anticarcinogenic effect of NSAIDs
(Figure 8); other anti-inflammatory reagents, such as IKK and
TNF antagonists, may also achieve similar SIR-targeted anticar-
cinogenic effects.
EXPERIMENTAL PROCEDURES
Human Samples
IHC studies on human intestinal polyp sections were approved by the institu-
tional review board of the Hadassah-HebrewUniversity Medical Center (HMO-
0109-11), verifying that informed consent is not required.
Mouse Breeding and Genotyping
CKIafl/fl;Villin-Cre-ERT2 (CKIaDgut), CKIafl/fl;p53fl/fl;Villin-Cre-ERT2 (CKIaDgut;
p53Dgut) and CKIafl/fl;p21/;Villin-Cre-ERT2 (CKIaDgut;p21/) mice were
generated as previously described (Elyada et al., 2011). APCMin/+ (Harlan)
mice were sacrificed at 3–5 months of age. Genotyping primers are listed in
the Supplemental Experimental Procedures. Mice were kept under specific
pathogen-free conditions at the Hadassah Medical School of the Hebrew Uni-
versity. All mouse experiments were approved by the Institutional Animal Care
and Use Committee (IACUC) of the Hebrew University-Hadassah Medical
School and performed in accordance with this committee’s guidelines.
Tamoxifen Administration; Sulindac, BV6, and BOT64 Treatments;
BrdU Labeling; and Tissue Preparation
Mice were injected with 150 mg/kg tamoxifen (Sigma) subcutaneously, six in-
jections every other day. Sulindac (Sigma) was administered in the drinking
water at 0.6 g/l, 1 week before the first tamoxifen injection and throughout
the 2 weeks of KO induction for a total period of 3 weeks. BV6 (Genentech)
was injected intraperitoneally at 10 mg/kg, every other day, from day 2 of
KO induction. BOT64 (Santa Cruz) was injected intraperitoneally at 30 mg/
kg, every day, fromday 2 of KO induction. One to two days after the last tamox-
ifen injection, mice were injected intraperitoneally with 10 ml/g of 5-bromo-2-
deoxyuridine (BrdU; GE Healthcare) and sacrificed 2 hr later, on day 10–12
of KO induction. Intestine was fixed in 4% formaldehyde for paraffin-
embedded sections (FFPE), or immediately embedded in Tissue-Tek OCT64 (DKO BOT) at day 5 of treatment (n = 2). Black arrows indicate budding
D; nR 60). *p = 0.046.
00 mM sulindac or 2.5 mM BOT64, compared with their floxed counterparts
untreated and treated with 500 mM sulindac or 2.5 mM BOT64.
reated with 500 mM sulindac or 2.5 mM BOT64. Counterstain: Hoechst (blue).
(APC KO) (n = 5), and DKO organoids (± SD). *p < 0.01.
0 ng/ml exogenous TNF compared with untreated WT controls (± SD; nR 60).
xogenous TNF compared with untreated WT controls. White arrows indicate
(legend on next page)
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Figure 8. A Schematic Model of Para-Inflammation Driving Gut
Homeostasis, or Tumorigenesis, Depending on the Status of p53
CKIa loss or the accumulation of several oncogenic mutations results in a
persistent DDR in normal epithelial tissue. Persistent DDR triggers SIR, a form
of para-inflammation, an intermediate between basal homeostasis and
chronic inflammation, which is confined to the epithelial tissue itself. In p53-
proficient tissue, SIR, accompanied by p53 activation, results in p21 activa-
tion, counterbalancing the excessive proliferation due to the oncogenic
effects, and thus tissue homeostasis is maintained. However, when p53 is
mutated or lost, p21 fails to be activated, resulting in a breach of homeostasis,
hyperproliferation, invasion, and carcinogenesis. NSAID treatment moderates
para-inflammation; consequently both the proproliferative (e.g., Wnt activa-
tion) and the proinvasive drive (e.g., PSIS expression) are suppressed, thus
helping to regain homeostasis.
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Senescence Switch Promotes Colorectal CancerCompound (Sakura) and frozen at80C for frozen sections. Intestinal epithe-
lial cells (IECs) were isolated as previously described (Elyada et al., 2011;
Greten et al., 2004; detailed in the Supplemental Experimental Procedures).
Histology, Immunohistochemistry, Immunofluorescence, and
Senescence-Associated b-Galactosidase Analysis
Five micrometer sections were cut for hematoxylin and eosin staining (H&E)
and IHC. Antibodies that were used in tissue staining are listed in the Supple-
mental Experimental Procedures. Diaminobenzidine chromogen (LabVision)
was used for detection of IHC. Hematoxylin was used as nuclear counterstain
for IHC. Senescence-associated b-galactosidase (SA-b-gal) staining was per-
formed on 10 mmsections of OCT-embedded frozen tissue, and the procedure
and antibodies conditions are detailed in the Supplemental Experimental
Procedures.Figure 7. SIR Inhibition Prevents Carcinogenesis in DKO Mice
(A) SA-b-gal staining (blue) in intestinal cryo-sections of CKIa;p21 DKO and sulin
(B) SA-b-gal staining (blue) in intestinal cryo-sections of Het, CKIa;p21 DKO,
Counterstain: nuclear fast red.
(C) H&E and IHC of BrdU, PROX1, and IFITM2/3 in intestinal sections of CKIa;p2
(D) H&E and IHC of BrdU, PROX1, and IFITM2/3 in intestinal sections of Het, C
BOT64) mice.
(E) Quantification of BrdU and PROX1 positive staining in villi of the different exp
neutralizenormal stainingwithin thecrypts. (Percentage±SEM;nR200villi.) p<0.0
(F) Quantification of high-grade dysplasia in villi of untreated DKO (n = 3), BOT64-t
values are represented by horizontal bars; n = 3). *p = 0.008, **p = 0.002.
See also Figure S5.
254 Cancer Cell 24, 242–256, August 12, 2013 ª2013 Elsevier Inc.Intestinal Crypt Cultures
Intestinal crypts from WT, APC KO, CKIa KO, and CKIa;p53 DKO mice
were isolated on the basis of the previously published methods (Sato
et al., 2009). Culturing of crypts is detailed in the Supplemental Experimental
Procedures. KO Induction was carried out by adding 300 nM 4-hydroxy-
tamoxifen (4OHT; Sigma) for 48 hr to organoid culture medium. Selection
for organoids with active Wnt/b-catenin pathway was done by splitting the
4OHT-induced organoids and culturing them without growth factors in the
medium. Organoids were treated with TNF (R&D, 100 ng/ml), neutralizing
goat anti-mouse TNF antibody (R&D, 2.5 mg/ml), sulindac (Sigma, 100 mM
or 500 mM), and BOT64 (Santa Cruz, 2.5 mM). The ratio of dead or nonbud-
ding organoids was calculated on day 4. Whole-mount staining of organoids
was done in four-well chamber slides (BD Biosciences) or on round
coverslips in a 24-well plate. Incubation with 10 uM BrdU was performed
for 16 hr. Incubation with the primary antibody was performed overnight
at 4C. More details can be found in the Supplemental Experimental
Procedures.
FACS, Western Blotting, and RNA Analysis
Immune cells (CD45.2-positive population) were sorted from the IEC
preparation using anti-CD45.2 antibody (1:200; BD Pharmingen). Whole-
cell protein extracts were isolated from IECs or intestinal crypt organoids
and analyzed with western blotting using a standard protocol. Antibodies
that were used are listed in the Supplemental Experimental Procedures.
HRP-linked secondary antibodies were used for detection (1:10,000;
Jackson). Blots were developed using ECL (GE Healthcare). Total RNA
was extracted from IECs using TRI-reagent (Sigma) and phenol/chloroform
methods, and from crypt cultures using the NucleoSpin RNA II Kit
(Macherey-Nagel). Reverse transcription was done using M-MLV-RT
(Invitrogen), and mRNA expression levels were measured with qRT-PCR
using SYBR-Green (Invitrogen) in a 7900HT Fast Real-Time PCR system
(ABI). Sequences of RT-PCR primers are listed in the Supplemental Experi-
mental Procedures. Relative quantities of gene transcripts were analyzed
in qBase 2.2 software and normalized to ubiquitin C, hypoxanthine-guanine
phosphoribosyltransferase, and/or glyceraldehyde-3-phosphate dehydroge-
nase transcripts.
RNA-seq Analysis
For RNA-seq, total RNA from IECs of CKIa+/Dgut (Het), CKIaDgut (KO) and
CKIaDgut;p53Dgut (DKO) mice was prepared as previously described, and
samples from three mice per genotype were pooled together. The RNA of
each genotype group was processed with the mRNA Sequencing Kit (Illumina)
and duplicate samples were subjected to multiplex sequencing using the
Illumina HiSeq2000 platform, according to the manufacturer’s protocol.
Analysis protocol is detailed in the Supplemental Experimental Procedures.
The RNA-seq full data can be found at http://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-1683/.
More details can be found in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.06.005.dac-treated CKIa;p21 DKO (DKO + Sul) mice. Counterstain: nuclear fast red.
BOT64-treated DKO (DKO BOT64), and BV6-treated DKO (DKO BV6) mice.
1 DKO and sulindac-treated CKIa;p21 DKO (DKO Sul) mice.
KIa;p21 DKO, BV6-treated DKO (DKO BV6), and BOT64-treated DKO (DKO
erimental groups. Staining quantification was restricted to villi compartment to
5. forbothBrdUandPROX1 inall three treatmentscompared tountreatedDKO.
reated DKO (DKO BOT64; n = 3), and BV6-treated DKO (DKO BV6) mice (mean
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